- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06352749
Face-to-face vs Online Physical Exercise in Seniors Living in Nursing Homes (ExerMOT-NH) (ExerMOT-NH)
Face-to-face vs Online Physical Exercise in Seniors Living in Nursing Homes: Randomized Controlled Trial on Its Effects on Health and Quality of Life
Study Overview
Status
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jon Irazusta, Prof
- Phone Number: +34946012837
- Email: jon.irazusta@ehu.eus
Study Contact Backup
- Name: Ana Rodriguez, Prof
- Phone Number: 34946012846
- Email: ana.rodriguez@ehu.eus
Study Locations
-
-
Bizkaia
-
Portugalete, Bizkaia, Spain, 48920
- Recruiting
- Residencia Aspaldiko
-
Contact:
- Alvaro Mosquera
- Phone Number: 34-946250000
- Email: amosquera@aspaldiko.org
-
Santurtzi, Bizkaia, Spain, 48980
- Not yet recruiting
- Residencia Nuestra Señora de Begoña
-
Contact:
- Janire R Ochoa
- Phone Number: 944836875
- Email: psicologa@residencia-santurtzi.com
-
Sestao, Bizkaia, Spain, 48910
- Not yet recruiting
- Residencia Albiz Santiago LLanos
-
Contact:
- Olatz Larrinaga
- Phone Number: 946572220
- Email: direccion@residenciaalbiz.eus
-
-
Vizcaya
-
Barakaldo, Vizcaya, Spain, 48902
- Not yet recruiting
- Fundación Miranda
-
Contact:
- Celia Gómez
- Phone Number: 944382675
- Email: innovación@fundaciónmiranda.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Older than 65 years
- A score equal to or higher than 15 out of 35 in the MEC-35 (Miniexamen Cognoscitivo) cognitive test
- A score equal to or higher than 50 out of 100 in the Barthel Index
- Able to stand-up and walk for 10 meters
Exclusion Criteria:
- Unstable Clinical Situation
- When the potential harms outweigh the benefits, according to the judgment of the healthcare personnel at the NHs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Sham Comparator: Control
Participants will receive advice to be physically active and to reduce their sedentary behavior
|
After the baseline assessments, all participants will receive individualized counseling for following physically active lifestyle and reducing sedentary behaviors.
Participants will be encouraged to increase the physical activity time and intensity, and to hourly break the sedentary time while at home.
The recommendations will be transmitted verbally and through written material.
|
|
Experimental: Online exercise
Participants will receive general recommendations for maintaining physically active and reducing sedentary behaviors.
This will be done verbally and through written material.
In addition, participants will take part in a 6-month multicomponent physical exercise program consisting of 2 online weekly multicomponent sessions.
|
After the baseline assessments, all participants will receive individualized counseling for following physically active lifestyle and reducing sedentary behaviors.
Participants will be encouraged to increase the physical activity time and intensity, and to hourly break the sedentary time while at home.
The recommendations will be transmitted verbally and through written material.
This intervention will entail: Strength training of upper and lower limbs. Familiarization phase will include 2-3 exercises of 1-2 series and 8-12 repetitions per session. During the acquisition phase, 2-3 exercises of 2-3 series and 8-12 repetitions at a higher velocity. The resting time between sets will be of 1-3 minutes. Balance exercises will include proprioception, agility and weight transfer exercises. Difficulty will progressively increase by reducing the base of support, by including multidirectional displacements, walking on tiptoe or heels, body-weight transfer, dynamic exercises modifying the centre of gravity, and stressing postural muscles and by sensorial reductions. Flexibility exercises: Static stretching maintained during 20-30s carried out at the end of each session. All the sessions will be supervised online by trained physiotherapists or sports physiologists. |
|
Active Comparator: Face-to-face exercise
Participants will receive general recommendations for maintaining physically active and reducing sedentary behaviors.
This will be done verbally and through written material.
In addition, participants will take part in a 6-month multicomponent physical exercise program consisting of 2 face-to-face weekly multicomponent sessions.
|
After the baseline assessments, all participants will receive individualized counseling for following physically active lifestyle and reducing sedentary behaviors.
Participants will be encouraged to increase the physical activity time and intensity, and to hourly break the sedentary time while at home.
The recommendations will be transmitted verbally and through written material.
This intervention will entail: Strength training of upper and lower limbs. Familiarization phase will include 2-3 exercises of 1-2 series and 8-12 repetitions per session. During the acquisition phase, 2-3 exercises of 2-3 series and 8-12 repetitions at a higher velocity. The resting time between sets will be of 1-3 minutes. Balance exercises will include proprioception, agility and weight transfer exercises. Difficulty will progressively increase by reducing the base of support, by including multidirectional displacements, walking on tiptoe or heels, body-weight transfer, dynamic exercises modifying the centre of gravity, and stressing postural muscles and by sensorial reductions. Flexibility exercises: Static stretching maintained during 20-30s carried out at the end of each session. All the sessions will be supervised face-to-face by trained physiotherapists or sports physiologists. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Trail Making Test (TMT)
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
The TMT is a valid and widely used test to assess executive functioning.
The TMT consists of two parts, part A and part B. Part A is based on number sequencing and assesses visual-perceptual abilities and participants have to draw lines to link numbers from 1 to 25 in ascending order.
Part B focus on number and letter switching evaluates cognitive flexibility and consists of drawing a line to link the numbers and the letters alternatively following in ascending order (e.g.
1-A-2-B-3-C).
The completion time will be registered in seconds.
Lower duration indicates better performance
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Spanish Version of the Yesavage Depression Scale
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
The Yesavage Depression Scale, also known as the Geriatric Depression Scale (GDS), is a widely used self-report questionnaire designed to detect symptoms of depression in older adults.
it consists 15 simple yes/no questions focusing on mood, cognition, and behavior.
The scale helps assess the severity of depressive symptoms and can aid in determining the need for further evaluation or intervention.
The scores range from 0 to 15.
Higher values indicate more depressive symptoms.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
30-seconds Chair Sit to Stand test
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
A test to measure muscle function of the lower limbs.
Starting in a seated position, participants will be instructed to perform as many full sit-to-stand cycles as they could in a 30-second timeframe with the number of cycles considered the score for this test.
Higher scores indicate better performance.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
MoCA (Montreal Cognitive Assessment)
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
MoCA test will be used to evaluate the cognitive function of participants.
The MoCA was designed as a rapid screening instrument for mild cognitive dysfunction (63).
It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation.
Time to administer the MoCA is approximately 10 minutes.
The total possible score ranged from 0 to 30.
Higher scores indicate better performance.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Wechsler Adult Intelligence Scale III (WAIS-III)
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
The WAIS-III is a test battery that has long been the gold standard for the evaluation of cognitive abilities (69).
Specifically, we only use the digit span to evaluate working memory (70).
Participants will be asked to recall a list of numbers in the order that they will be given (forward or backwards).
The test is finished when for the same item the participant fails two attempts.
A total number of correct answers will be registered for each condition.
Higher values indicate better performance.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
EuroQol-5 dimensions (EQ-5D-5L)
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
European Quality of Life-5 Dimensions (EQ-5D) questionnaire.
Participants will self-rate their health on a vertical visual analogue scale (score range: 0-100), where the endpoints are labeled 'The worst health you can imagine' and 'The best health you can imagine'.
Higher values indicate better quality of life.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
The Spanish adaptation of the Basic Psychological Needs in Exercise Scale (BPNES) (Moreno et al., 2008)
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
The BPNES will be used to evaluate the satisfaction of the needs perceived by the participants (73).
This questionnaire includes 12 items distributed in three dimensions (autonomy, competence and the other four items measure the relationship).
The score ranges from 12 to 60. Higher values indicates a greater fulfillment of basic needs in physical exercise.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Zung's Anxiety Self-Assessment Scale (Hernández-Pozo, et al., 2008)
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
The Zung Anxiety Scale is a self-report questionnaire to measure the severity of anxiety symptoms in individuals.
It consists of 20 questions related to various aspects of anxiety, such as physical symptoms, cognitive aspects, and emotional manifestations.
Respondents rate each item based on how frequently they experience each symptom.
The scale provides a quantitative assessment of anxiety levels, helping professionals to identify individuals experiencing significant anxiety symptoms and determine appropriate interventions.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Satisfaction with Life Scale
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
It is a 5-question scale with Likert-type answers of 5 categories that examines de global grade of satisfaction with life.
Possible answers go from absolutely untrue (1) to absolutely true (5).
A score of 5 to 25 points can be obtained.
Higher values indicate better satisfaction with life.
The score ranges from 5 to 35.
Higher values indicate greater satisfaction.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Short Physical Performance Battery (SPPB)
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
The SPPB consists of three tasks that evaluate the lower extremities' function: balance, walking speed and sit-to-stand 5 times from a chair.
In each task 0 to 4 points can be scored, to obtain a total score between 0 and 12 points.
Higher values indicate better function.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
The Biceps Curl Test
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
This requires people to repeatedly lift a 5 lb (2.27 kg) weight (for women) or an 8 lb (3.63 kg) weight (for men) for 30 seconds.
The number of lifts is recorded.
This reflects upper body strength.
Higher values indicate better performance.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
The 2-minute Walk Test (2-MWT)
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
2-MWT is an adaptation of 6-MWT.
The test measured distance in meters walked in 2 minutes and reflects aerobic endurance.
The original version of the Senior Fitness Test required people to walk on a rectangular course but more recent versions use a straight line.
Higher values indicate better performance.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
The 8 Feet Up-and-Go test
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
The test measures the time the subject needs to stand from a chair, walk 8 feet (2,5 meters), turn around, get back to the chair, and sit.
The longer the time to complete the test, the worse the performance.
Leaning on the thighs or the chair is allowed to stand.
Lower time indicates better performance.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Handgrip strength test
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
The grip strength of each hand will be measured with a manual dynamometer.
This variable is related to the general strength of the subject, where higher values indicate greater strength
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum Brain Derived Neurotrophic Factor (BDNF)
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning after an overnight fast and at least 24 h after the last exercise session. After collection, tubes will be centrifuged at 5000 rpm for 10 min. Serum obtained for each participant will be stored in aliquots at -80 °C until analysis. Serum BDNF (ng/mL) will be quantified using a sandwich enzyme-linked immunosorbent assay (ELISA). Human BDNF Quantikine Immunoassay (R &D Systems, Minneapolis, MN) will be performed according to the manufacturer's instructions. Results will be reported as ng/mL. |
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum Klotho
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
Following collection, the tubes will be centrifuged at 5000×g for 10 min.
The serum obtained from each participant will be stored in aliquots at - 80 °C for further analysis.
A commercial enzyme-linked immunosorbent assay (ELISA) will be performed to measure klotho serum concentration according to the manufacturer's protocol (Human soluble α-Klotho Assay Kit JP27998, Immuno-Biological Laboratories Co., Ltd., Gunma, Japan).
The quantification will be performed spectrophotometrically using a FLUOstar OPTIMA Microplate Reader (ThermoFisher Scientific, Waltham, MA, USA) and Optima Control software version 2.20.
Results will be reported as ng/mL.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum Glucose
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The glucose concentration (mg/dL) will be measured in blood serum using routine clinical techniques.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum Urea
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The urea concentration (mg/dl) will be measured in blood serum using routine clinical techniques.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum Creatinine
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The concentration (mg/dL) will be measured in blood serum using routine clinical techniques.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum Uric Acid
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The uric acid concentration (mg/dL) will be measured in blood serum using routine
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum Cholesterol
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The cholesterol concentration (mg/dL) will be measured in blood serum using routine clinical techniques.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum Triglycerides
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The triglyceride concentration (mg/dL) will be measured in blood serum using routine clinical techniques.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum HDL-Cholesterol
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The HDL-Cholesterol concentration (mg/dL) will be measured in blood serum using routine clinical techniques.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum LDL-Cholesterol
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The LDL-Cholesterol concentration (mg/dL) will be measured in blood serum using routine clinical techniques.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum Glutamate Pyruvate Transaminase
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
Serum glutamate pyruvate transaminase activity will be measured in blood serum using routine clinical techniques.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum Glutamate Oxaloacetate Transaminase
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The glutamate oxaloacetate transaminase activity will be measured in blood serum using routine clinical techniques.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum gamma glutamyl transferase
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The gamma glutamyl transferase activity will be measured in blood serum using routine clinical techniques.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum Alkaline Phosphatase
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The alkaline phosphatase activity will be measured in blood serum using routine clinical techniques.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum Creatin Kinase
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The creatin kinase activity will be measured in blood serum using routine clinical techniques.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum Lactate Dehydrogenase
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The lactate dehydrogenase activity will be measured in blood serum using routine clinical techniques.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum Bilirubin
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The bilirubin concentration (mg/dL) will be measured in blood serum using routine clinical techniques.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum Sodium
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The sodium concentration (mEq/L) will be measured in blood serum using routine clinical techniques.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum Potassium
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The potassium concentration (mEq/L) will be measured in blood serum using routine clinical techniques.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum Chloride
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The chloride concentration (mEq/L) will be measured in blood serum using routine clinical techniques.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum C Reactive Protein
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The C reactive protein concentration (mg/dL) will be measured in blood serum using routine clinical techniques.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum Albumin
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The albumin concentration (g/dL) will be measured in blood serum using routine clinical techniques
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum Total Protein
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The total protein concentration (g/L) will be measured in blood serum using routine clinical techniques
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum Calcium
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The calcium concentration (mg/dL) will be measured in blood serum using routine clinical techniques
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum Phosphorus
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The phosphorus concentration (mg/dL) will be measured in blood serum using routine clinical techniques
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Serum D Vitamin
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The D vitamin concentration (ng/dL) will be measured in blood serum using routine clinical techniques
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Erythrocyte count
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The number of erythrocytes will be measured in blood using routine clinical techniques
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Hemoglobin
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The hemoglobin concentration will be measured in blood using routine clinical techniques
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Hematocrit
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The hematocrit will be calculated in blood using routine clinical techniques
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Mean Corpuscular Volume (MCV)
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The mean corpuscular volume will be measured in blood using routine clinical techniques
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Mean Corpuscular Hemoglobin (MCH)
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Baseline blood samples will be collected in the morning following an overnight fast.
The mean corpuscular hemoglobin will be measured in blood using routine clinical techniques.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Mean Corpuscular Hemoglobin Concentration (MCHC)
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The mean corpuscular hemoglobin concentration will be measured in blood using routine clinical techniques
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Red Cell Distribution Width (RDW)
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The red cell distribution width will be measured in blood using routine clinical techniques
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Leucocyte Count
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The number of leucocytes will be measured in blood using routine clinical techniques
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Neutrophil Count and Percentage
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The number of neutrophils will be measured in blood using routine clinical techniques.
The percentage of neutrophils in the total white blood cell count will be calculated.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Lymphocyte Count and Percentage
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The number of lymphocytes will be measured in blood using routine clinical techniques.
The percentage of lymphocytes in the total white blood cell count will be calculated.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Monocyte Count and Percentage
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The number of monocytes will be measured in blood using routine clinical techniques.
The percentage of monocytes in the total white blood cell count will be calculated
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Eosinophil Count and Percentage
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The number of eosinophils will be measured in blood using routine clinical techniques.
The percentage of eosinophils in the total white blood cell count will be calculated
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Basophil Count and Percentage
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The number of basophils will be measured in blood using routine clinical techniques.
The percentage of basophils in the total white blood cell count will be calculated
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Platelet Count
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The number of platelets will be measured in blood using routine clinical techniques.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Platelet Mean Volumen
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Blood samples will be collected in the morning following an overnight fast.
The mean volume of platelets will be measured in blood using routine clinical techniques.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Physical activity, sedentary lifestyle and sleep will be evaluate using accelerometry
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Physical activity level was recorded with an accelerometer (Actigraph GT3X model; Actigraph LLC, Pensacola, FL, USA) that participants wore on the wrist with a belt for 7 days.
Participants did not receive additional instructions to walk during the assessment period.
The accelerometer was set to record the number of steps taken per day.
Active-period intensities were classified as light, moderate, or vigorous, and were measured in minutes per day at each intensity.
Sedentary time, bouts and breaks will be also recorded.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Fried's frailty phenotype score
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
Frailty will be analyzed with the 5 criteria suggested by Fried: unintentional weight loss, weakness or poor handgrip strength, self-reported exhaustion, slow walking speed, and low physical activity.
The presence of each criterion will be scored with one point, the total score ranging between 0-5 points.
A higher score indicates higher frailty.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Frail-NH frailty scale
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
It consist of 6 items Fatigue, resistance, ambulation, nutritional approach and help with dressing.
Each item could receive a score from 0 to 2 and total score ranges from 0 to 13.
An score < 6 is defined as non-frail; 6-7 as prefrail and > 7 as frail.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
The Pittsburgh Sleep Quality Index
Time Frame: At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval.
Nineteen individual items generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction.
The sum of scores for these seven components yields one global score.
The Score ranges from 0 to 21.
Higher values indicate worse sleep.
|
At baseline, after 24 weeks of intervention and after 24 weeks follow-up
|
|
Attendance rate
Time Frame: During 24 weeks of intervention
|
Attendance rate to face-to-face sessions will be calculated as the percentage of sessions attended out of the actual number of sessions offered.
Reasons for non-attendance will be also provided
|
During 24 weeks of intervention
|
|
Dose modification
Time Frame: During 24 weeks of intervention
|
Dose modifications (intensity or volume) in each session will be recorded.
The number and percentage of dose modification will be calculated and provided.
|
During 24 weeks of intervention
|
|
Adverse Events
Time Frame: During 24 weeks of intervention
|
Adverse events (safety and technical) in each session will be recorded.
The number and percentage of each type of adverse event will be calculated and provided.
|
During 24 weeks of intervention
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jon Irazusta, Prof, University of the Basque Country (UPV/EHU)
Publications and helpful links
General Publications
- Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56. doi: 10.1093/gerona/56.3.m146.
- Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4.
- Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA, Wallace RB. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994 Mar;49(2):M85-94. doi: 10.1093/geronj/49.2.m85.
- Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x. Erratum In: J Am Geriatr Soc. 2019 Sep;67(9):1991.
- Pin TW. Psychometric properties of 2-minute walk test: a systematic review. Arch Phys Med Rehabil. 2014 Sep;95(9):1759-75. doi: 10.1016/j.apmr.2014.03.034. Epub 2014 May 9.
- Llinas-Regla J, Vilalta-Franch J, Lopez-Pousa S, Calvo-Perxas L, Torrents Rodas D, Garre-Olmo J. The Trail Making Test. Assessment. 2017 Mar;24(2):183-196. doi: 10.1177/1073191115602552. Epub 2016 Jul 28.
- Rodriguez-Larrad A, Arrieta H, Rezola C, Kortajarena M, Yanguas JJ, Iturburu M, Susana MG, Irazusta J. Effectiveness of a multicomponent exercise program in the attenuation of frailty in long-term nursing home residents: study protocol for a randomized clinical controlled trial. BMC Geriatr. 2017 Feb 23;17(1):60. doi: 10.1186/s12877-017-0453-0.
- Herdman M, Badia X, Berra S. [EuroQol-5D: a simple alternative for measuring health-related quality of life in primary care]. Aten Primaria. 2001 Oct 15;28(6):425-30. doi: 10.1016/s0212-6567(01)70406-4. No abstract available. Spanish.
- Martínez de la Iglesia J, Onís-Vilches MC, Dueñas-Herrero R, et ál. Versión española del cuestionario de Yesavage abreviado (GDS) para el despistaje de depresión en mayores de 65 años: adaptación y validación. Medifam. 2002; 12(10):620.
- Rikli, R.E., Jones, C.J. Senior Fitness Test. Champaign: Human Kinetics; 2001. (ISBN 0-7360- 3356-3364).
- Wechsler D. WAIS III: escala de inteligencia de Wechsler para adultos-III manual técnico. Madrid: TEA; 1999
- Moreno, J. A., González-Cutre, D., Chillón, M., y Parra, N. (2008). Adaptación a la educación física de la escala de las necesidades psicológicas básicas en el ejercicio. Revista Mexicana de Psicología, 25(2), 295-303
- Hernández-Pozo, M., Macías, D., Calleja, N., Cerezo, S., & del Valle Chauvet, C. (2008). Propiedades psicometricas del inventario Zung del estado de ansiedad con mexicanos. Psychologia. Avances de la disciplina, 2(2), 19-46.
- Vazquez C, Duque A, Hervas G. Satisfaction with life scale in a representative sample of Spanish adults: validation and normative data. Span J Psychol. 2013;16:E82. doi: 10.1017/sjp.2013.82.
- Fess EE. Grip strength. In: Casanova JS, editor. Clinical assessment recommendations, 2nd ed. Chicago: American Society of Hand Therapists; 1992. pp. 41-45.
- Kaehr E, Visvanathan R, Malmstrom TK, Morley JE. Frailty in nursing homes: the FRAIL-NH Scale. J Am Med Dir Assoc. 2015 Feb;16(2):87-9. doi: 10.1016/j.jamda.2014.12.002. Epub 2014 Dec 31. No abstract available.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BasqueCU2024
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cognitive Decline
-
China Medical University HospitalNot yet recruitingSubjective Cognitive Decline | Subjective Cognitive Decline (SCD)Taiwan
-
Jean-François DémonetUniversity of Lausanne HospitalsActive, not recruitingCognitive Performance | Functional Capacity | Subjective Cognitive Decline | Age-related Cognitive DeclineSwitzerland
-
Rotman Research Institute at BaycrestSunnybrook Health Sciences Centre; University of Waterloo; Toronto Rehabilitation... and other collaboratorsTerminatedSubjective Cognitive Decline | Age-Related Cognitive DeclineCanada
-
University of Social Sciences and Humanities, WarsawNational Science Centre, Poland; Sanprobi Sp. z o. o.Active, not recruitingCognitive Decline | Cognitive Aging | Memory DeclinePoland
-
National Taiwan University HospitalNational Taiwan Science Education Center(NTSEC)CompletedCognitive Training | Subjective Cognitive DeclineTaiwan
-
Vanderbilt University Medical CenterCompleted
-
Wageningen UniversityRoquette Frères; Sensus BV; Cosun Nutrition Center; Oceanium Ltd.; Technical University...Active, not recruitingSubjective Cognitive DeclineNetherlands
-
IRCCS Centro San Giovanni di Dio FatebenefratelliUniversity of ChietiCompletedSubjective Cognitive DeclineItaly
-
National Cheng Kung UniversityUnknownEffects of Cognitive Strategy Training on Daily Function in People With Subjective Cognitive DeclineSubjective Cognitive DeclineTaiwan
-
University Hospital TuebingenCompletedSubjective Cognitive DeclineGermany
Clinical Trials on Advice to increase physical activity and reduce sedentary behavior
-
Fundació Universitària del BagesAlthaia Xarxa Assistencial Universitària de ManresaNot yet recruitingQuality of Life | Obesity | Weight Loss
-
University of Social Sciences and Humanities, WarsawRecruitingPsychotic Disorders | Affective DisorderPoland
-
University of Colorado, DenverCompleted
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases | ObesityUnited States
-
Hospital Universitari Vall d'Hebron Research InstituteSpanish Society of Pneumology and Thoracic SurgeryUnknownChronic Obstructive Pulmonary Disease | Physical Activity | Sedentary LifestyleSpain
-
Northwestern UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Centre of Postgraduate Medical EducationCompletedPulmonary Arterial Hypertension | Physical InactivityPoland
-
The Miriam HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedPhysical Activity | Weight Loss | Health-related Quality of LifeUnited States
-
Karolinska InstitutetRegion StockholmCompletedType 2 Diabetes Mellitus | ExerciseSweden